Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences
company developing a new generation of bio-innovative biologic
medicines to improve patient delivery, access, safety and
convenience, today announced the appointment of Janice Marie
McCourt as Chief Business Officer.
In her role at Comera, Ms. McCourt will be responsible for
business development, including evaluation and execution of
out-licensing, in-licensing and strategic transaction
opportunities, and driving the execution of the Company’s
commercial strategy. Ms. McCourt will report to Jeffrey Hackman,
Chairman and CEO, and serve on the Company’s executive leadership
team, working closely with the other members of the executive
leadership team to secure commercial partnership opportunities and
advance the Company's pipeline of drug candidates.
“We are delighted to welcome Janice to our leadership team as
our Chief Business Officer at this critical time of accelerated
growth,” said Jeffrey Hackman, Chief Executive Officer and Chairman
of Comera. “Janice has extensive business development and
leadership expertise, a successful track record in corporate
deal-making and a deep industry network that further strengthens
our executive team as we execute on strategies to build value
across our internal and partnered programs. We are well-positioned
to help maximize the true potential of life-changing biologics by
transforming them from intravenous to subcutaneous forms that
patients can administer themselves.”
“Comera’s expertise and commitment to bringing innovative
solutions to patients coupled with its exciting growth prospects
makes this an exciting time to join their team,” said Janice Marie
McCourt, Chief Business Officer of Comera. “I am a pharmacist at
heart, and I see the clear value and potential of Comera’s
technology to lead a compassionate new era in medicine by
transforming blockbuster medications from IV to out-patient
subcutaneous patient-administered injection, providing patients and
their families with more freedom to fully realize the potential of
life-changing therapies.”
Ms. McCourt brings more than 30 years of biotechnology and
pharmaceutical experience. Prior to joining Comera, Ms. McCourt was
the Chief Business and Corporate Development Officer at Lyvgen
Biopharma, a private biotechnology company focused on developing
innovative immuno-oncology therapies, where she focused on
corporate strategy, business and clinical operations, finance,
corporate development, alliance management, negotiation of
partnerships, licensing deals and research and development
collaborations. Prior to Lyvgen, she led business and corporate
development and alliances for Heat Biologics, Edgemont
Pharmaceuticals, Agenus, and Amakem Therapeutics.
Ms. McCourt also served as Senior Vice President of Business
Development and Marketing for Ingenix, a health care information,
technology and research company and a wholly owned subsidiary of
UnitedHealth Group. Prior to Ingenix, she was Vice President of
Corporate Development and Marketing at ActivBiotics, a
biotechnology company focused on developing and commercializing
antibiotics and combination therapies for the treatment of acute
and chronic infections. Ms. McCourt’s prior biotechnology and
pharmaceutical experience also includes roles in business
development, marketing, medical affairs, training, corporate
communications, and investor relations at Praecis Pharmaceuticals,
Abbott Laboratories, and Takeda. She has led or supported the
commercial strategy of more than one hundred products that have
advanced from clinical development through regulatory approval
globally with billions in sales.
Ms. McCourt holds a B.S. in Pharmacy on a full academic
scholarship, with a specialization in Industrial Pharmacy from the
Massachusetts College of Pharmacy and Health Sciences, and
graduated summa cum laude with an MBA from the University of
Phoenix in General Management.
Inducement Grant Under Nasdaq Listing Rule
5635(c)(4)
In connection with Ms. McCourt’s appointment as Chief Business
Officer, the Company granted her a non-statutory stock option to
purchase 150,000 shares of the Company’s common stock with an
exercise price of $1.36 per share, the closing price on November 8,
2022. The stock options have a ten-year term and vest over four
years, with one-fourth vesting on November 1, 2023, and the
remaining three-fourths vesting in equal monthly installments
thereafter, subject to her continued employment on each applicable
vesting date.
The grant was made as an inducement that was a material
component of Ms. McCourt's compensation and subsequent acceptance
of employment with the Company and was granted as an employment
inducement award pursuant to Nasdaq Listing Rule 5635(c)(4)
approved by the Company's Compensation Committee and Board of
Directors.
About Comera Life Sciences
Leading a compassionate new era in medicine, Comera Life
Sciences is applying a deep knowledge of formulation science and
technology to transform essential biologic medicines from
intravenous (IV) to subcutaneous (SQ) forms. The goal of this
approach is to provide patients with the freedom of self-injectable
care, reduce institutional dependency and to put patients at the
center of their treatment regimen.
To learn more about the Comera Life Sciences mission, as well as
the proprietary SQore™ platform, visit
https://comeralifesciences.com/.
Forward-Looking StatementsThis press release
contains “forward-looking statements” within the meaning of the
federal securities laws that reflect Comera's plans, estimates,
assumptions, and beliefs, including statements about the potential
of the Company’s SQore™ platform to transform essential
biologic medicines from IV to SQ forms based on the strength of
preclinical results from the SEQURUS-2 study. These forward-looking
statements generally are identified by the words “believe,”
“project,” “expect,” “anticipate,” “estimate,” “intend,”
“strategy,” “future,” “opportunity,” “plan,” “may,” “should,”
“will,” “would,” “will be,” “will continue,” “will likely result,”
and similar expressions. Forward-looking statements are
predictions, projections and other statements about future events
that are based on current expectations and assumptions and, as a
result, are subject to risks and uncertainties. Many factors could
cause actual future events to differ materially from the
forward-looking statements in this document, including, but not
limited to: risks that the recently completed business combination
disrupts the Company’s current plans and ability to retain its
employees; the Company’s ability to maintain the listing of its
securities on the Nasdaq Capital Market; the effect of the COVID-19
pandemic on the Company’s business; the price of the Company’s
securities may be volatile due to a variety of factors, including
changes in the competitive and highly regulated industries in which
the Company plans to operate, variations in performance across
competitors, changes in laws and regulations affecting the
Company’s business and changes in the capital structure; the
ability to implement business plans, forecasts, and other
expectations and identify and realize additional opportunities; the
risk of downturns and the possibility of rapid change in the highly
competitive industry in which the Company operates; the risk that
the Company and its current and future collaborators are unable to
successfully develop and commercialize the Company’s products or
services, or experience significant delays in doing so; the risk
that we will be unable to continue to attract and retain
third-party collaborators, including collaboration partners and
licensors; the risk that the Company may never achieve or sustain
profitability; the risk that the Company will need to raise
additional capital to execute its business plan, which may not be
available on acceptable terms or at all; the risk that the Company
experiences difficulties in managing its growth and expanding
operations; the risk that third-party suppliers and manufacturers
are not able to fully and timely meet their obligations; the risk
that the Company is unable to secure or protect its intellectual
property; the risk that the Company is unable to secure regulatory
approval for its product candidates; general economic conditions;
and other risks and uncertainties indicated in the Current Report
on Form 8-K filed with the SEC on May 25, 2022 under “Risk Factors”
and in other filings that have been made or will be made with the
SEC. The foregoing list of factors is not exhaustive. You should
carefully consider the foregoing factors and the other risks and
uncertainties described in the “Risk Factors” section of Comera’s
Current Report on Form 8-K filed with the SEC on May 25, 2022, and
other documents filed by Comera from time to time with the SEC.
These filings identify and address other important risks and
uncertainties that could cause actual events and results to differ
materially from those contained in the forward-looking statements.
Forward-looking statements speak only as of the date they are made.
Readers are cautioned not to put undue reliance on forward-looking
statements, and Comera assumes no obligation and does not intend to
update or revise these forward-looking statements, whether as a
result of new information, future events, or otherwise. Comera can
give no assurance that it will achieve its expectations.
Contacts
Comera Investor John Woolford ICR Westwicke
John.Woolford@westwicke.com
Comera Press ICR
WestwickeComera@westwicke.com
Comera Life Sciences (NASDAQ:CMRA)
Historical Stock Chart
From Apr 2024 to May 2024
Comera Life Sciences (NASDAQ:CMRA)
Historical Stock Chart
From May 2023 to May 2024